Figure 4From: Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agentsDesign of the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (Neo-ALTTO) study. ER, estrogen receptor; FEC, fluorouracil, epirubicin, and cyclophosphamide; LVEF, left ventricular ejection fraction; PgR, progesterone receptor; T, trastuzumab.Back to article page